Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid

Author(s):
Ferrari, M.D. (0000-0001-9691-9449); Zuurbier, K.W.M.; Barash, S.; Ning, X.P.; Cohen, J.M.
Published
2022
Publication type
Article / Letter to editor
chronic migrainefremanezumabonabotulinumtoxinAtopiramatevalproic acid
Date issued
2022-04-06
Language
English
Publisher
WILEY
Is part of
hdl
1887/3505075
doi
10.1111/head.14294